Candel Therapeutics (CADL) to Release Earnings on Thursday

Posted by Stanley Muller on Aug 11th, 2026

Candel Therapeutics (NASDAQ:CADL – Get Free Report) is expected to be posting its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Candel Therapeutics to post earnings of ($0.22) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.16. On average, analysts expect Candel Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Candel Therapeutics Stock Down 0.8%

Candel Therapeutics stock opened at $10.50 on Tuesday. The company has a 50-day simple moving average of $9.48 and a 200-day simple moving average of $7.27. The firm has a market capitalization of $769.34 million, a P/E ratio of -10.71 and a beta of -0.51. The company has a debt-to-equity ratio of 0.34, a quick ratio of 28.05 and a current ratio of 28.05. Candel Therapeutics has a one year low of $4.35 and a one year high of $11.36.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on CADL shares. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target on shares of Candel Therapeutics in a research note on Wednesday, July 29th. Stifel Nicolaus started coverage on Candel Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $22.00 price objective for the company. Wall Street Zen raised Candel Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a report on Friday, July 17th. Finally, Cantor Fitzgerald assumed coverage on shares of Candel Therapeutics in a research report on Monday, April 20th. They issued an “overweight” rating on the stock. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.57.

Get Our Latest Analysis on Candel Therapeutics

Insider Activity

In other news, CTO Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $10.02, for a total transaction of $70,140.00. Following the completion of the sale, the chief technology officer directly owned 83,865 shares in the company, valued at $840,327.30. The trade was a 7.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Francesca Barone sold 23,447 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $10.06, for a total transaction of $235,876.82. Following the completion of the sale, the insider directly owned 77,362 shares of the company’s stock, valued at $778,261.72. This represents a 23.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 14.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Candel Therapeutics

A number of institutional investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in Candel Therapeutics in the fourth quarter worth about $134,000. Price T Rowe Associates Inc. MD boosted its holdings in Candel Therapeutics by 31.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 25,814 shares of the company’s stock valued at $146,000 after purchasing an additional 6,176 shares in the last quarter. MetLife Investment Management LLC grew its stake in shares of Candel Therapeutics by 25.5% in the 4th quarter. MetLife Investment Management LLC now owns 19,443 shares of the company’s stock valued at $110,000 after purchasing an additional 3,955 shares during the period. LPL Financial LLC grew its stake in shares of Candel Therapeutics by 33.9% in the 4th quarter. LPL Financial LLC now owns 28,653 shares of the company’s stock valued at $162,000 after purchasing an additional 7,250 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Candel Therapeutics by 28.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,520 shares of the company’s stock worth $109,000 after buying an additional 4,772 shares in the last quarter. Institutional investors own 13.93% of the company’s stock.

About Candel Therapeutics

(Get Free Report)

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.